Challenges and controversies in the treatment of prolactinomas

References

• Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91(12):4769-75
   PubMed Web of Science ®Google Scholar
• Fontana E, Gaillard R. Epidemiology of pituitary adenoma: results of the first Swiss study. Rev Med Suisse 2009;5(223):2172-4
   PubMedGoogle Scholar
• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010;72(3):377-82
   PubMed Web of Science ®Google Scholar
• Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 2013;16(4):545-53
   PubMed Web of Science ®Google Scholar
• Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27(5):485-534
   PubMed Web of Science ®Google Scholar
• Sclechte A. Clinical practice. Prolactinoma. N Engl J Med 2003;349(21):2035-41
   PubMedGoogle Scholar
• Davis JR, Farrell WE, Clayton RN. Pituitary tumours. Reproduction 2001;121(3):363-71
   PubMed Web of Science ®Google Scholar
• Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65(2):265-73
   PubMed Web of Science ®Google Scholar
• Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005;8(1):3-6
   PubMedGoogle Scholar
• Colao A, Sarno AD, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003;148(3):325-31
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273-88
   PubMed Web of Science ®Google Scholar
• Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics 2014;55(1):29-36
   PubMed Web of Science ®Google Scholar
• Y N Sinha. Structural variants of prolactin: occurrence and physiological significance. Endocrine Reviews 1995;16(3):354-69
   PubMed Web of Science ®Google Scholar
• Vilar L, Fleseriu M, Bronstein MD. Challenge and pitfall in the diagnosis in hyperprolactinemia. Arq Bras Endocrinol Metab 2014;58(1)):9-22
   PubMedGoogle Scholar
• Jackson RD, Wortsman J, Malarkey WB. Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol Metab 1985;61(2):258-64
   PubMed Web of Science ®Google Scholar
• Shimatsu A, Hattori N. Macroprolactinemia: diagnostic, clinical, and pathogenic significance. Clin Dev Immunol 2012;2012:167132
   PubMedGoogle Scholar
• Vilar L, Naves LA, Freitas MC, et al. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia. Minerva Endocrinol 2007;32(2):79-86
   PubMedGoogle Scholar
• Theunissen C, de Schepper J, Schiettecatte J, et al. Macroprolactinemia: clinical significance and characterization of the condition. Acta Clinica Belgica 2005;60(4):190-7
   PubMed Web of Science ®Google Scholar
• Elenkova A, Genov N, Abadzhieva Z, et al. Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance. Exp Clin Endocrinol Diabetes 2013;121(4):201-5
   PubMed Web of Science ®Google Scholar
• Fahie-Wilson M, Smith TP. Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metab 2013;27(5):725-42
   PubMed Web of Science ®Google Scholar
• Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol 2011;7(5):267-78
   PubMed Web of Science ®Google Scholar
• Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84(7):2518-22
   PubMed Web of Science ®Google Scholar
• Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001;86(11):5256-61
   PubMed Web of Science ®Google Scholar
• Yamaji T, Ishibashi M, Kosaka K, et al. Pituitary apoplexy in acromegaly during bromocriptine therapy. Acta Endocrinol(Copenh.) 1981;98:171-7
   PubMedGoogle Scholar
• Pinto G, Zerah M, Trivin C, Brauner R. Pituitary apoplexy in an adolescent with prolactin-secreting adenoma. Horm Res 1998;50:38-41
   PubMedGoogle Scholar
• Knoepfelmacher M, Gomes MC, Melo ME, Mendonca BB. Pituitary Apoplexy During Therapy with Cabergoline in an Adolescent Male with Prolactin-Secreting Macroadenoma. Pituitary 2004;7:83-7
   PubMedGoogle Scholar
• Shirataki K, Chihara K, Shibata Y, et al. Pituitary apoplexy manifested during a bromocriptine test in a patient with growth hormone and prolactin producing pituitary adenoma. Neurosurgery 1988;23:395-8
   PubMed Web of Science ®Google Scholar
• Chng E, Dalan R. Pituitary apoplexy associated with cabergoline therapy. J Clin Neurosci 2013;20(12):1637-43
   PubMed Web of Science ®Google Scholar
• Webster J, Piscitelli G, Polli A, et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clin Endocrinol (Oxf) 1993;39(3):323-9
   PubMed Web of Science ®Google Scholar
• Nawar RN, AbdelMannan D, Selman WR, Arafah BM. Pituitary tumor apoplexy: a review. J Intensive Care Med 2008;23:75-90
   PubMed Web of Science ®Google Scholar
• Laws ER. Pituitary tumor apoplexy: a review. J Intensive Care Med 2008;23:146-7
   PubMedGoogle Scholar
• Carija R, Vucina D. Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review. CNS Neurol Disord Drug Targets 2012;11(8):1012-14
   PubMed Web of Science ®Google Scholar
• Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003;88(10):4709-19
   PubMed Web of Science ®Google Scholar
• Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly - the experience of a dedicated pituitary surgeon. QJM 1999;92(12):741-5
   PubMedGoogle Scholar
• Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152(1):61-6
   PubMed Web of Science ®Google Scholar
• Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 2012;166(5):779-86
   PubMed Web of Science ®Google Scholar
• Vroonen L, Jaffrain-Rea ML, Petrossians P, et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 2012;167(5):651-62
   PubMed Web of Science ®Google Scholar
• Yang MS, Hong JW, Lee SK, et al. Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist. J Neurooncol 2011;104(1):195-204
   PubMed Web of Science ®Google Scholar
• Grossman A, Cohen BL, Charlesworth M, et al. Treatment of prolactinomas with megavoltage radiotherapy. Br Med J (Clin Res Ed) 1984;288(6424):1105-9
   PubMedGoogle Scholar
• Pan L, Zhang N, Wang EM, et al. Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg 2000;93(Suppl 3):10-13
   PubMedGoogle Scholar
• Tsagarakis S, Grossman A, Plowman PN, et al. Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up. Clin Endocrinol (Oxf) 1991;34(5):399-406
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Fowble BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986;81(3):457-62
   PubMed Web of Science ®Google Scholar
• Erridge SC, Conkey DS, Stockton D, et al. Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol 2009;93:597-601
   PubMed Web of Science ®Google Scholar
• Leber KA, Bergloff J, Pendl G. Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. J Neurosurg 1998;88:43-50
   PubMed Web of Science ®Google Scholar
• Tishler RB, Loeffler JS, Lunsford LD, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993;27(2):215-21
   PubMed Web of Science ®Google Scholar
• Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005;90(2):800-4
   PubMed Web of Science ®Google Scholar
• McCutcheon IE. Pituitary adenomas: surgery and radiotherapy in the age of molecular diagnostics and pathology. Curr Probl Cancer 2013;37(1):6-37
   PubMed Web of Science ®Google Scholar
• Oh MC, Tihan T, Kunwar S, et al. Clinical management of pituitary carcinomas. Neurosurg Clin N Am 2012;23(4):595-606
   PubMed Web of Science ®Google Scholar
• Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 2005;8:43-52
   PubMedGoogle Scholar
• Delgrange E, Duprez T, Maiter D. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol (Oxf) 2006;64(4):456-62
   PubMed Web of Science ®Google Scholar
• Raverot G, Wierinckx A, Dantony E, et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 2010;95(4):1708-16
   PubMed Web of Science ®Google Scholar
• Mallea-Gil MS, Cristina C, Perez-Millan MI, et al. Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers. Endocr Pathol 2009;20:35-40
   PubMed Web of Science ®Google Scholar
• Behan LA, Draman MS, Moran C, et al. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary 2011;14:362-6
   PubMed Web of Science ®Google Scholar
• Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994;60:314-22
   PubMed Web of Science ®Google Scholar
• Wu ZB, Zheng WM, Su ZP, et al. Expression of D2RmRNA isoforms and ERmRNA iso- forms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. J Neurooncol 2010;99:25-32
   PubMed Web of Science ®Google Scholar
• Barlier AB, Pellegrini-Bouiller IP, Caccavelli L, et al. Abnormal transduction mechanisms in pituitary adenomas. Horm Res 1997;47:227-34
   PubMedGoogle Scholar
• Shimazu S, Shimatsu A, Yamada S, et al. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels. Eur J Endocrinol 2012;166:383-90
   PubMed Web of Science ®Google Scholar
• Li Q, Su Z, Liu J, et al. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine. Mol Cell Endocrinol 2013;13:00461-9
   Google Scholar
• Missale C, Boroni F, Losa M, et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 1993;90(17):7961-5
   PubMed Web of Science ®Google Scholar
• Caccavelli L, Morange-Ramos I, Kordon C, et al. Alteration of Ga subunits mRNA levels in bromocriptine resistant adenomas. J Neuroendocrinol 1996;8:737-46
   PubMed Web of Science ®Google Scholar
• Filopanti M, Lania AG, Spada A. Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas. Expert Opin Drug Metab Toxicol 2010;6(1):43-53
   PubMed Web of Science ®Google Scholar
• Molitch ME. Management of medically refractory prolactinoma. J Neurooncol 2014;117(3):421-8
   PubMed Web of Science ®Google Scholar
• Sauder SE, Frager M, Case GD, et al. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine. J Clin Endocrinol Metab 1984;59:941-8
   PubMed Web of Science ®Google Scholar
• Winters SJ, Troen P. Altered pulsatile secretion of luteinizing hormone in hypogonadal men with hyperprolactinaemia. Clin Endocrinol 1984;21:257-63
   PubMed Web of Science ®Google Scholar
• Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 2011;25(6):885-96
   PubMed Web of Science ®Google Scholar
• Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996;14:228-38
   PubMed Web of Science ®Google Scholar
• Divers WA Jr, Yen SS. Prolactin-producing microadenomas in pregnancy. Obstet Gynecol 1983;62:425-9
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Perone Y, Di Sarno A, et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 2013;98(1):372-9
   PubMed Web of Science ®Google Scholar
• Domingue ME, Devuyst F, Alexopoulou O, et al. Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol (Oxf) 2014;80(5):642-8
   PubMed Web of Science ®Google Scholar
• Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson’s disease. N Engl J Med 2005;353(10):1021-7
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102(23):2836-41
   PubMed Web of Science ®Google Scholar
• Jähnichen S, Horowski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 2005;513(3):225-8
   PubMed Web of Science ®Google Scholar
• Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356(1):6-9
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356(1):29-38
   PubMed Web of Science ®Google Scholar
• Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007;356(1):39-46
   PubMed Web of Science ®Google Scholar
• Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005;353(18):1976-7
   PubMed Web of Science ®Google Scholar
• Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363(9416):1179-83
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Livadariu E, Markov M, et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008;159(1):1-5
   PubMed Web of Science ®Google Scholar
• Elenkova A, Shabani R, Kalinov K, Zacharieva S. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol 2012;167(1):17-25
   PubMed Web of Science ®Google Scholar
• Wakil A, Rigby AS, Clark AL, et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008;159(4):R11-14
   Web of Science ®Google Scholar
• Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009;12(3):153-7
   PubMed Web of Science ®Google Scholar
• Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 2009;70(1):104-8
   PubMed Web of Science ®Google Scholar
• Lafeber M, Stades AM, Valk GD, et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol 2010;162(4):667-75
   PubMed Web of Science ®Google Scholar
• Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf) 2010;73(3):369-74
   PubMed Web of Science ®Google Scholar
• Steffensen C, Maegbaek ML, Laurberg P, et al. Heart valve disease among patients with hyperprolactinemia: a nationwide population-based cohort study. J Clin Endocrinol Metab 2012;97(5):1629-34
   PubMed Web of Science ®Google Scholar
• Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008;93(10):3777-84
   PubMed Web of Science ®Google Scholar
• Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008;93(9):3348-56
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol 2013;169(3):359-66
   PubMed Web of Science ®Google Scholar
• Trifirò G, Mokhles MM, Dieleman JP, et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Saf 2012;35(2):159-71
   PubMed Web of Science ®Google Scholar
• Maione L, Garcia C, Bouchachi A, et al. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J Clin Endocrinol Metab 2012;97(9):E1714-19
   PubMed Web of Science ®Google Scholar
• Delgado V, Biermasz NR, van Thiel SW, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf) 2012;77(1):99-105
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003;349(21):2023-33
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Guerra E, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 2007;67(3):426-33
   PubMed Web of Science ®Google Scholar
• Huda MS, Athauda NB, Teh MM, et al. Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol (Oxf) 2010;72(4):507-11
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Adamidou F, Polyzos SA, et al. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary 2012;15(1):25-9
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Lagro J, Burman P, et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95(1):43-51
   PubMed Web of Science ®Google Scholar
• Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 2009;94(7):2428-36
   PubMed Web of Science ®Google Scholar
• Kaltsas GA, Nomikos P, Kontogeorgos G, et al. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90(5):3089-99
   PubMed Web of Science ®Google Scholar
• Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013;126(1):123-35
   PubMed Web of Science ®Google Scholar
• Ironside JW. Best Practice No 172: pituitary gland pathology. J Clin Pathol 2003;56(8):561-8
   PubMed Web of Science ®Google Scholar
• Ragel BT, Couldwell WT. Pituitary carcinoma: a review of the literature. Neurosurg Focus 2004;16(4):E7
   PubMedGoogle Scholar
• Petrossians P, de Herder W, Kwekkeboom D, et al. Malignant prolactinoma discovered by D2 receptor imaging. J Clin Endocrinol Metab 2000;85(1):398-401
   PubMed Web of Science ®Google Scholar
• Gollard R, Kosty M, Cheney C, et al. Prolactin-secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. A case report and literature review. Cancer 1995;76(10):1814-20
   PubMed Web of Science ®Google Scholar
• Walker JD, Grossman A, Anderson JV, et al. Malignant prolactinoma with extracranial metastases: a report of three cases. Clin Endocrinol (Oxf) 1993;38:411-19
   PubMed Web of Science ®Google Scholar
• Kaltsas GA, Grossman AB. Malignant pituitary tumours. Pituitary 1998;1(1):69-81
   PubMedGoogle Scholar
• Ahmed M, Kanaan I, Alarifi A, et al. ACTH-producing pituitary cancer: experience at the King Faisal Specialist Hospital & Research Centre. Pituitary 2000;3(2):105-12
   PubMedGoogle Scholar
• Kaltsas GA, Mukherjee JJ, Plowman PN, et al. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 1998;83(12):4233-8
   PubMed Web of Science ®Google Scholar
• Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 2012;76(6):769-75
   PubMed Web of Science ®Google Scholar
• Losa M, Mazza E, Terreni MR, et al. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 2010;163(6):843-51
   PubMed Web of Science ®Google Scholar
• Mohammed S, Kovacs K, Mason W, et al. Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 2009;64(4):E773-4
   PubMed Web of Science ®Google Scholar
• Whitelaw BC, Dworakowska D, Thomas NW, et al. Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) 2012;76(6):877-86
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Beckers A. Update on familial pituitary tumors: from multiple endocrine neoplasia type 1 to familial isolated pituitary adenoma. Horm Res 2009;71(Suppl 1):105-11
   PubMed Web of Science ®Google Scholar
• Vergès B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002;87(2):457-65
   PubMed Web of Science ®Google Scholar
• Beckers A, Betea D, Valdes Socin H, Stevenaert A. The treatment of sporadic versus MEN1-related pituitary adenomas. J Intern Med 2003;253(6):599-605
   PubMed Web of Science ®Google Scholar
• Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006;91(9):3316-23
   PubMed Web of Science ®Google Scholar
• Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial isolated pituitary adenomas(FIPA) and the pituitary adenoma predisposition due to mutations in the arylhydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 2013;34(2):239-77
   PubMed Web of Science ®Google Scholar
• Cuny T, Pertuit M, Sahnoun-Fathallah M, et al. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don’t forget MEN1 genetic analysis. Eur J Endocrinol 2013;168(4):533-41
   PubMed Web of Science ®Google Scholar
• Tichomirowa MA, Barlier A, Daly AF, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 2011;165(4):509-15
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 2010;95(11):E373-83
   PubMed Web of Science ®Google Scholar
• Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998;9138:1455-61
   Google Scholar